Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
Sionna Therapeutics (Nasdaq: SION) announced management will participate in investor fireside chats in March 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sionna Therapeutics (Nasdaq: SION) announced management will participate in investor fireside chats in March 2026. Events include TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 2:30 p.m. ET and Leerink Partners Global Healthcare Conference on March 10, 2026 at 1:40 p.m. ET.
Live webcasts and replays will be available in the Investors section at https://investors.sionnatx.com/.
Details
News Market Reaction – SION
On Feb 23, the day this news came out, SION closed 1.72% above the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
Key Figures
- TD Cowen conference date
- March 2, 2026
- TD Cowen 46th Annual Health Care Conference presentation date
- TD Cowen presentation time
- 2:30 p.m. ET
- Scheduled time for Sionna fireside chat
- Leerink conference date
- March 10, 2026
- Leerink Partners Global Healthcare Conference presentation date
- Leerink presentation time
- 1:40 p.m. ET
- Scheduled time for Sionna fireside chat
Historical Context
-
Announcement of Guggenheim Emerging Outlook biotech summit presentation and webcast details.
-
Participation in the 44th Annual J.P. Morgan Healthcare Conference with webcast access.
-
Planned fireside chats at two December 2025 healthcare investor conferences.
-
Q3 2025 results plus Phase 2a and Phase 1 trial initiations and strong cash position.
-
Scheduled November 2025 fireside chats at Guggenheim and Stifel healthcare conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cystic fibrosis medical
cftr protein medical
webcasts technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:
- TD Cowen 46th Annual Health Care Conference on Monday, March 2nd, 2026, at 2:30 p.m. ET; and
- Leerink Partners Global Healthcare Conference 2026 on Tuesday, March 10th, 2026, at 1:40 p.m. ET
Live webcasts of the presentations can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com/. Replays will also be available following the events.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.